The marine environment is a rich source of biologically active molecules for the treatment of
human diseases, especially cancer. The adaptation to unique environmental conditions led …

In 2019, the scientific and medical community celebrated the 50th anniversary of the
introduction of the very first marine-derived drug, Cytarabine, into clinics. Cytarabine (aka …

During 2005 and 2006, marine pharmacology research directed towards the discovery and
development of novel antitumour agents was reported in 171 peer-reviewed articles. The …

The marine environment represents an outstanding source of antitumoral compounds and,
at the same time, remains highly unexplored. Organisms living in the sea synthesize a wide …

By the end of the year 2020, there are nine marine-derived anticancer drugs available on
the market, and the field is currently growing exponentially. This process is stipulated by …

Marine secondary metabolites are a promising source of unexploited drugs that have a wide
structural diversity and have shown a variety of biological activities. These compounds are …

Cancer remains one of the most lethal diseases worldwide. There is an urgent need for new
drugs with novel modes of action and thus considerable research has been conducted for …

During 2003 and 2004, marine pharmacology research directed towards the discovery and
development of novel anti-tumour agents was published in 163 peer-reviewed articles. The …

The sea, covering 70% of the Earth's surface, offers a considerably broader spectrum of
biological diversity than terra firma. Containing approximately 75% of all living organisms …

Marine ecosystems contain over 80% of the world's biodiversity, and many of these
organisms have evolved unique adaptations enabling survival in diverse and challenging …